Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt 95.32
ENZ's Cash-to-Debt is ranked higher than
69% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. ENZ: 95.32 )
Ranked among companies with meaningful Cash-to-Debt only.
ENZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: N/A Max: No Debt
Current: 95.32
Equity-to-Asset 0.83
ENZ's Equity-to-Asset is ranked higher than
81% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ENZ: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
ENZ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.86 Max: 0.97
Current: 0.83
0.01
0.97
Interest Coverage 646.81
ENZ's Interest Coverage is ranked higher than
63% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. ENZ: 646.81 )
Ranked among companies with meaningful Interest Coverage only.
ENZ' s Interest Coverage Range Over the Past 10 Years
Min: 345.61  Med: No Debt Max: No Debt
Current: 646.81
Piotroski F-Score: 7
Altman Z-Score: 17.23
Beneish M-Score: -2.37
WACC vs ROIC
8.19%
135.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 32.88
ENZ's Operating Margin % is ranked higher than
97% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. ENZ: 32.88 )
Ranked among companies with meaningful Operating Margin % only.
ENZ' s Operating Margin % Range Over the Past 10 Years
Min: -39.63  Med: -19.63 Max: 45.73
Current: 32.88
-39.63
45.73
Net Margin % 31.57
ENZ's Net Margin % is ranked higher than
98% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. ENZ: 31.57 )
Ranked among companies with meaningful Net Margin % only.
ENZ' s Net Margin % Range Over the Past 10 Years
Min: -38.09  Med: -16.58 Max: 44.06
Current: 31.57
-38.09
44.06
ROE % 41.17
ENZ's ROE % is ranked higher than
96% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. ENZ: 41.17 )
Ranked among companies with meaningful ROE % only.
ENZ' s ROE % Range Over the Past 10 Years
Min: -56.99  Med: -16.22 Max: 68.53
Current: 41.17
-56.99
68.53
ROA % 32.77
ENZ's ROA % is ranked higher than
98% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. ENZ: 32.77 )
Ranked among companies with meaningful ROA % only.
ENZ' s ROA % Range Over the Past 10 Years
Min: -43.97  Med: -13.85 Max: 50.26
Current: 32.77
-43.97
50.26
ROC (Joel Greenblatt) % 250.95
ENZ's ROC (Joel Greenblatt) % is ranked higher than
97% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. ENZ: 250.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENZ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -230.98  Med: -98.58 Max: 330.82
Current: 250.95
-230.98
330.82
3-Year Revenue Growth Rate -2.30
ENZ's 3-Year Revenue Growth Rate is ranked lower than
71% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. ENZ: -2.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENZ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.7  Med: 5.3 Max: 28.9
Current: -2.3
-15.7
28.9
GuruFocus has detected 5 Warning Signs with Enzo Biochem Inc $ENZ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENZ's 30-Y Financials

Financials (Next Earnings Date: 2017-09-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ENZ Guru Trades in Q2 2016

Jim Simons 1,866,981 sh (+28.77%)
» More
Q3 2016

ENZ Guru Trades in Q3 2016

Jim Simons 1,957,368 sh (+4.84%)
» More
Q4 2016

ENZ Guru Trades in Q4 2016

Jim Simons 1,965,500 sh (+0.42%)
» More
Q1 2017

ENZ Guru Trades in Q1 2017

Jim Simons 2,042,400 sh (+3.91%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:NTRA, NYSE:ARA, NAS:VIVO, NYSE:NVTA, NAS:PACB, NAS:SRDX, NAS:LNTH, NAS:RDNT, NAS:HSKA, NAS:NEO, NAS:MGEN, NAS:NRCIA, NAS:ONVO, AMEX:SENS, NAS:ALOG, LSE:MXCT, NAS:CTSO, NAS:PMD, NAS:AIQ, XKRX:950140 » details
Traded in other countries:EZB.Germany,
Headquarter Location:USA
Enzo Biochem Inc is engaged in research, development, manufacturing and marketing of health care products, platforms and services. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.

Enzo Biochem Inc was founded in 1976. It is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. The Company develops, manufactures and sells its proprietary technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. The Enzo Clinical Labs is a clinical reference laboratory provides clinical services to a physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Underpinned by broad technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information by laboratories around the world. The Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. It owns or license 314 patents relating to products, methods and procedures resulting from its internal or sponsored research projects. The Company distributes its life science products internationally through a network of distributors. It competes with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. The Company is subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens, infectious and hazardous waste.

Top Ranked Articles about Enzo Biochem Inc

Is the S&P 500 the Right Portfolio for You? Take a look at these charts and decide what is best for you
The U.S. is the world’s biggest free-market economy. Over many years, the value of stocks traded on U.S. stock markets (as judged by market cap) have traditionally fluctuated between 33% and 43% of all publicly traded issues worldwide. Read more...

Ratios

vs
industry
vs
history
PE Ratio 15.51
ENZ's PE Ratio is ranked higher than
87% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. ENZ: 15.51 )
Ranked among companies with meaningful PE Ratio only.
ENZ' s PE Ratio Range Over the Past 10 Years
Min: 5.25  Med: 11.89 Max: 34.86
Current: 15.51
5.25
34.86
PE Ratio without NRI 15.51
ENZ's PE Ratio without NRI is ranked higher than
87% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. ENZ: 15.51 )
Ranked among companies with meaningful PE Ratio without NRI only.
ENZ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.25  Med: 11.89 Max: 34.86
Current: 15.51
5.25
34.86
Price-to-Owner-Earnings 18.63
ENZ's Price-to-Owner-Earnings is ranked higher than
74% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. ENZ: 18.63 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ENZ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.99  Med: 12.91 Max: 31.48
Current: 18.63
4.99
31.48
PB Ratio 5.84
ENZ's PB Ratio is ranked lower than
69% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ENZ: 5.84 )
Ranked among companies with meaningful PB Ratio only.
ENZ' s PB Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.94 Max: 7.17
Current: 5.84
0.85
7.17
PS Ratio 4.90
ENZ's PS Ratio is ranked lower than
59% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. ENZ: 4.90 )
Ranked among companies with meaningful PS Ratio only.
ENZ' s PS Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.05 Max: 13.22
Current: 4.9
0.56
13.22
Price-to-Free-Cash-Flow 16.12
ENZ's Price-to-Free-Cash-Flow is ranked higher than
76% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. ENZ: 16.12 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ENZ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.62  Med: 11.34 Max: 22.28
Current: 16.12
4.62
22.28
Price-to-Operating-Cash-Flow 15.36
ENZ's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. ENZ: 15.36 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENZ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.48  Med: 10.67 Max: 18.63
Current: 15.36
4.48
18.63
EV-to-EBIT 13.19
ENZ's EV-to-EBIT is ranked higher than
84% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ENZ: 13.19 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -65.1  Med: -6.7 Max: 32.4
Current: 13.19
-65.1
32.4
EV-to-EBITDA 11.94
ENZ's EV-to-EBITDA is ranked higher than
77% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. ENZ: 11.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.7  Med: -8.25 Max: 76.5
Current: 11.94
-43.7
76.5
Current Ratio 5.16
ENZ's Current Ratio is ranked higher than
74% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ENZ: 5.16 )
Ranked among companies with meaningful Current Ratio only.
ENZ' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 6.54 Max: 33.9
Current: 5.16
0.2
33.9
Quick Ratio 4.73
ENZ's Quick Ratio is ranked higher than
76% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ENZ: 4.73 )
Ranked among companies with meaningful Quick Ratio only.
ENZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 6.13 Max: 33.15
Current: 4.73
0.17
33.15
Days Inventory 44.50
ENZ's Days Inventory is ranked higher than
63% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. ENZ: 44.50 )
Ranked among companies with meaningful Days Inventory only.
ENZ' s Days Inventory Range Over the Past 10 Years
Min: 44.5  Med: 60.2 Max: 75.03
Current: 44.5
44.5
75.03
Days Sales Outstanding 54.30
ENZ's Days Sales Outstanding is ranked higher than
57% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. ENZ: 54.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.29  Med: 50.46 Max: 99.02
Current: 54.3
45.29
99.02
Days Payable 58.94
ENZ's Days Payable is ranked higher than
52% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. ENZ: 58.94 )
Ranked among companies with meaningful Days Payable only.
ENZ' s Days Payable Range Over the Past 10 Years
Min: 29.18  Med: 55.95 Max: 64.59
Current: 58.94
29.18
64.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
ENZ's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. ENZ: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENZ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.4  Med: -2.1 Max: 0
Current: -4.5
-20.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.64
ENZ's Price-to-Net-Cash is ranked higher than
55% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.16 vs. ENZ: 11.64 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ENZ' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.26  Med: 8.97 Max: 737
Current: 11.64
3.26
737
Price-to-Net-Current-Asset-Value 7.45
ENZ's Price-to-Net-Current-Asset-Value is ranked higher than
60% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. ENZ: 7.45 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ENZ' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.37  Med: 5.92 Max: 238
Current: 7.45
2.37
238
Price-to-Tangible-Book 6.65
ENZ's Price-to-Tangible-Book is ranked lower than
59% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. ENZ: 6.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ENZ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.97  Med: 5.03 Max: 124.5
Current: 6.65
1.97
124.5
Price-to-Intrinsic-Value-Projected-FCF 5.17
ENZ's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
78% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. ENZ: 5.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ENZ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.82  Med: 4.01 Max: 410
Current: 5.17
1.82
410
Price-to-Median-PS-Value 2.39
ENZ's Price-to-Median-PS-Value is ranked lower than
92% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. ENZ: 2.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENZ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 2.67 Max: 23.46
Current: 2.39
0.18
23.46
Price-to-Graham-Number 2.14
ENZ's Price-to-Graham-Number is ranked higher than
70% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. ENZ: 2.14 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ENZ' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.03  Med: 4.38 Max: 21.06
Current: 2.14
1.03
21.06
Earnings Yield (Greenblatt) % 7.58
ENZ's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. ENZ: 7.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENZ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -94.8  Med: -9.6 Max: 26.8
Current: 7.58
-94.8
26.8
Forward Rate of Return (Yacktman) % 2.70
ENZ's Forward Rate of Return (Yacktman) % is ranked lower than
66% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. ENZ: 2.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ENZ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -31.2  Med: -5 Max: 16.7
Current: 2.7
-31.2
16.7

More Statistics

Revenue (TTM) (Mil) $106.24
EPS (TTM) $ 0.72
Beta0.99
Short Percentage of Float1.78%
52-Week Range $4.88 - 12.04
Shares Outstanding (Mil)46.41

Analyst Estimate

Jul17
Revenue (Mil $)
EPS ($) -0.15
EPS without NRI ($) -0.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ENZ

Headlines

Articles On GuruFocus.com
Is the S&P 500 the Right Portfolio for You? Apr 03 2017 
Weekly CFO Buys Highlight: BWEN, DDMG, ZHNE, ENZ, SIRO Nov 28 2011 
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Mar 14 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Jun 09 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2009 
Weekly Top Insider Buys: Bank of America Corp., Safeway Inc., Umpqua Holdings Corp., National Penn B Oct 24 2009 
Weekly Top Insider Buys: KB Home, National Penn Bancshares Inc., Moduslink Global Solutions Inc., En Oct 20 2009 
Enzo Biochem Inc. Reports Operating Results (10-Q) Sep 04 2009 

More From Other Websites
Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session Jul 21 2017
Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab Jul 20 2017
Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt Jul 19 2017
Perrigo Company Gets FDA Approval for Generic Topical Gel Jul 18 2017
Arena Announces Secondary Stock Worth $150M (revised) Jul 17 2017
Can Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate Revisions? Jul 14 2017
BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug Jul 13 2017
5 Stocks with Recent Price Strength to Enhance Your Returns Jul 13 2017
Top 5 Biotech Stocks for 2017 Jul 12 2017
Arena Announces Secondary Stock Offering of 150M Shares Jul 12 2017
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta... Jul 12 2017
Roche (RHHBY) Announces Positive Data on Hemophilia A Drug Jul 11 2017
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half Jul 11 2017
ETFs with exposure to Enzo Biochem, Inc. : July 10, 2017 Jul 10 2017
DBV Technologies (DBVT) Worth a Look: Stock Up 5.7% Jul 10 2017
Endo (ENDP) to Remove Opioid Pain Drug Opana ER from Market Jul 07 2017
Shire Completes NDA Filing for Hemophilia Drug with FDA Jul 07 2017
Alexion Reportedly Being Investigated by HHS, Shares Slip Jul 07 2017
Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session Jul 06 2017
Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6% Jul 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}